Caris Life Sciences Inc. (CAI)

A handful of IPOs and blank checks priced in the short holiday week, led by two sizable issuers. Two smaller IPOs also priced this past week. One IPO is currently scheduled to list in the week ahead, ...

Caris Life Sciences is experiencing rapid growth, leveraging AI and molecular science for personalized medicine, but remains deeply unprofitable despite narrowing losses. The IPO was strong, with shar...

Live Updates Live Coverage Has Ended IPO Soars 12:56 pm by Gerelyn Terzo The markets embraced healthcare newcomer Caris Life Sciences (Nasdaq: CAI) today, marking its debut on the Nasdaq. After pricin...

Live Updates Live Coverage Updates appear automatically as they are published. Today's IPO Receives Warm Welcome 12:53 pm by Gerelyn Terzo The markets rolled out the welcome mat for healthcare st...

On Wednesday morning, the cancer diagnostics biotech firm Caris Life Sciences rang Nasdaq's opening bell in New York, marking the company's awaited initial public offering.

Shares of Caris Life Sciences soared in their public debut Wednesday, as investors bought into the company's business of molecular profiling and drug research using artificial intelligence.

The biotechnology company started trading at $27 each on Wednesday afternoon, a day after the company's IPO was priced at $21 a share. The stock was recently up 26% and trading at $26.48.

Caris Life Sciences' shares jumped nearly 29% in their New York debut on Wednesday, fetching the cancer diagnostic firm a valuation of $7.66 billion and signaling a growing investor appetite for new l...

Caris Life Sciences raised $494.1 million in its Nasdaq initial public offering, the cancer diagnostic firm said on Tuesday, amid a rebound in the IPO market.